AiCure announced it has completed a $12 million loan refinancing and has also raised an additional $4 million+ from its existing supportive investors. In 2023 company also expanded its customer base driven in part by its Clinical Site Services offering which provides ongoing monitoring of site- and patient-level data, targeting operational outcome improvements in adherence and compliance.

AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150.